Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02514083
Title A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Heart, Lung, and Blood Institute (NHLBI)

chronic lymphocytic leukemia/small lymphocytic lymphoma

chronic lymphocytic leukemia


Fludarabine + Ibrutinib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.